FDA’s Concerns With Unapproved GLP-1 Drugs Used For Weight Loss From Harlem To Hawaii
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss. Become a Harlem Insider! Sign-Up for our Newsletter *Constant Contact Use. Please leave this field blank.By submitting this form, you are consenting…